Breaking News Instant updates and real-time market news.

DE

Deere

$103.36

-0.56 (-0.54%)

, COP

ConocoPhillips

$46.44

0.69 (1.51%)

10:29
11/28/16
11/28
10:29
11/28/16
10:29

On The Fly: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Deere (DE) upgraded to Neutral from Underweight at Piper Jaffray with analyst Brett Wong saying investors will likely continue to pay "lofty multiples" since a bottom of the cycle is close. 2. ConocoPhillips (COP) upgraded to Conviction Buy from Neutral at Goldman with analyst Neil Mehta saying ConocoPhillips offers the most attractive free cash yield among U.S. majors/E&P and believes the company will grow its production through the ned of the decade. 3. Comerica (CMA) upgraded to Buy from Hold at Jefferies with analyst Ken Usdin saying the company's earnings are likely to benefit more than peers from higher short-term interest rates and a potentially lower Federal tax rate. 4. DuPont Fabros (DFT) upgraded to Outperform from Neutral at Baird with analyst David Rodgers citing its future development opportunity, solid corporate execution, and valuation. 5. Horizon Pharma (HZNP) upgraded to Buy from Neutral at Citi analyst Liav Abraham saying the risk/reward as favorable into the upcoming pivotal data for Actimmune in Friederich's Ataxia. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

DE

Deere

$103.36

-0.56 (-0.54%)

COP

ConocoPhillips

$46.44

0.69 (1.51%)

CMA

Comerica

$62.19

0.03 (0.05%)

DFT

DuPont Fabros

$42.19

0.81 (1.96%)

HZNP

Horizon Pharma

$21.49

-0.21 (-0.97%)

  • 28

    Nov

  • 29

    Nov

  • 29

    Nov

  • 29

    Nov

  • 05

    Dec

  • 13

    Dec

  • 14

    Dec

DE Deere
$103.36

-0.56 (-0.54%)

11/28/16
PIPR
11/28/16
UPGRADE
Target $100
PIPR
Neutral
Deere upgraded to Neutral from Underweight at Piper Jaffray
Piper Jaffray analyst Brett Wong upgraded Deere and others in the Agriculture space to Neutral saying investors will likely continue to pay "lofty multiples" since a bottom of the cycle is close. The analyst raised his price target for the shares to $100 from $70.
11/25/16
BARD
11/25/16
NO CHANGE
Target $117
BARD
Outperform
Deere price target raised to $117 from $105 at Baird
Baird analyst Mig Dobre raised his price target on Deere to $117 from $105 following its Q4 earnings beat. Dobre cited the above consensus guidance and said consistent with his recent upgrade, he believes a large agriculture equipment bottom is in sight with profitability remaining remarkably resilient. Dobre reiterated his Outperform rating on Deere shares.
11/25/16
UBSW
11/25/16
NO CHANGE
Target $105
UBSW
Buy
Deere price target raised to $105 from $87 at UBS
UBS analyst Steven Fisher raised his price target on Deere to $105 from $87 following its Q4 earnings beat. The analyst noted results significantly exceeded guidance for the year on strong performance in A&T and improved pricing power. Fisher, who expects the primary negatives for the stock from the past few years to be neutralizing, reiterated his Buy rating on Deere shares.
11/28/16
BMOC
11/28/16
NO CHANGE
BMOC
Deere price target raised to $120 from $96 at BMO Capital
BMO Capital analyst Joel Tiss raised his price target on Deere after the company reported stronger than expected Q4 results. The analyst says that the company's outlook has improved significantly, and he notes that it said that agricultural markets have bottomed. Tiss keeps an Outperform rating on the shares.
COP ConocoPhillips
$46.44

0.69 (1.51%)

11/15/16
11/15/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. FedEx (FDX) downgraded to Hold from Buy at Stifel with analyst David Ross citing valuation, as well as concerns about the "still-fragile global economic environment" and the integration of its TNT acquisition. 2. Abercrombie & Fitch (ANF) downgraded to Underperform at FBR Capital while the firm also downgraded American Eagle (AEO) to Market Perform from Outperform. 3. Amplify Snack Brands (BETR) downgraded to Perform from Outperform at Oppenheimer and to Neutral from Outperform at Credit Suisse. 4. BP (BP) downgraded to Outperform from Buy at CLSA while the firm also downgraded ConocoPhillips (COP) to Underperform from Outperform. 5. Cheesecake Factory (CAKE) downgraded to Hold from Buy at Maxim with analyst Stephen Anderson saying he sees the company's above-peer comps, market share gains, and solid new unit development prospects as being priced in after the 22% jump in the stock from its late October low. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/15/16
LYON
11/15/16
DOWNGRADE
Target $47
LYON
Underperform
ConocoPhillips downgraded to Underperform at CLSA
As previously reported, CLSA downgraded ConocoPhillips to Underperform and maintained its $47 price target. Analyst Asit Sen said ConocoPhillips' lack of Delaware/Midland exposure is a significant negative when compared to peers and prefers more aggressive moves to lower debt instead of the $3B announced buyback.
11/15/16
LYON
11/15/16
DOWNGRADE
LYON
Underperform
ConocoPhillips downgraded to Underperform from Outperform at CLSA
11/28/16
GSCO
11/28/16
UPGRADE
GSCO
Conviction Buy
ConocoPhillips upgraded to Conviction Buy from Neutral at Goldman
Goldman analyst Neil Mehta upgraded ConocoPhillips to Conviction Buy and raised its price target to $54 from $47. Mehta said ConocoPhillips offers the most attractive free cash yield among US majors/E&P and believes the company will grow its production through the ned of the decade. Further, the analyst expects capex to stay low and expects capital returns to grow in 2017-18, with 4%-10% dividend growth, and a $1B/yr buyback.
CMA Comerica
$62.19

0.03 (0.05%)

11/28/16
JEFF
11/28/16
UPGRADE
Target $74
JEFF
Buy
Comerica upgraded to Buy from Hold at Jefferies
Jefferies analyst Ken Usdin upgraded Comerica to Buy saying the company's earnings are likely to benefit more than peers from higher short-term interest rates and a potentially lower Federal tax rate. The analyst raised his price target for the shares to $74 from $56.
11/14/16
SDLR
11/14/16
DOWNGRADE
Target $60
SDLR
Hold
Comerica downgraded to Hold from Buy at Sandler O'Neill
Sandler O'Neill analyst Scott Siefers downgraded Comercia to Hold with a $60 price target citing recent shares strength.
11/10/16
11/10/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Comerica (CMA) downgraded to Neutral from Outperform at Baird with analyst David George saying he sees a more balanced risk/reward as the company is already getting significant credit for earnings leverage from its efficiency program. 2. Qualcomm (QCOM) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst James Faucette saying Qualcomm's valuation adequately reflects incremental smartphone opportunities and NXP Semiconductor (NXPI) contribution. 3. CSX (CSX) downgraded to Market Perform from Outperform at BMO Capital with analyst Fadi Chamoun saying the company will be hurt in the near-term by "an over-supplied trucking market," while its cost savings are expected to decelerate next year and macro economic trends will become less favorable to the company. 4. SolarEdge (SEDG) downgraded to Market Perform from Outperform at JMP Securities, to Market Perform from Outperform at FBR Capital, and to Neutral from Buy at Roth Capital. 5. Capitala Finance (CPTA) downgraded to Perform from Outperform at Oppenheimer and to Neutral from Buy at Ladenburg. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/10/16
BARD
11/10/16
DOWNGRADE
Target $52
BARD
Neutral
Comerica downgraded to Neutral at Baird
As reported previously, Baird analyst David George downgraded Comerica to Neutral from Outperform. The analyst sees a more balanced risk/reward as the company is already getting significant credit for earnings leverage from its efficiency program. George maintained his $52 price target on Comerica shares, also citing its highly asset-sensitive balance sheet, and moderating energy credit risk.
DFT DuPont Fabros
$42.19

0.81 (1.96%)

11/28/16
BARD
11/28/16
UPGRADE
BARD
Outperform
DuPont Fabros upgraded to Outperform from Neutral at Baird
11/28/16
BARD
11/28/16
UPGRADE
Target $44
BARD
Outperform
DuPont Fabros upgraded to Outperform at Baird
As reported previously, David Rodgers upgraded DuPont Fabros to Outperform from Neutral based on its future development opportunity, solid corporate execution, and valuation. Rodger maintained his $44 price target on DuPont Fabros shares.
10/28/16
RBCM
10/28/16
UPGRADE
RBCM
Outperform
DuPont Fabros upgraded on 'unwarranted weakness' at RBC Capital
As noted earlier, RBC Capital upgraded DuPont Fabros to Outperform from Sector Perform. Analyst Jonathan Atkin says that the company reported "solid" Q3 results,. while the weakness in the stock in the wake of the results was "unwarranted," creating a positive risk/reward ratio. Target to $49 from $48.
10/28/16
RBCM
10/28/16
UPGRADE
RBCM
Outperform
DuPont Fabros upgraded to Outperform from Sector Perform at RBC Capital
HZNP Horizon Pharma
$21.49

-0.21 (-0.97%)

10/12/16
GSCO
10/12/16
NO CHANGE
Target $26
GSCO
Buy
Horizon Pharma risk/reward attractive, says Goldman
Goldman analyst Stephan Stewart lowered Horizon Pharma 2016-2020 EBITDA estimates 4%-7% largely due to increase in investments across its primary care and orphan franchises following the guidance update. Stewart said the investments fit with Horizon's ongoing transition toward higher growth orphan sales against a more sustainable primary care base. He also sees potential synergy upside from the pending Raptor deal as a source of some 2017 offset. The analyst lowered Horizon's price target to $26 from $27 but said risk/reward is attractive and reiterates his Buy rating.
10/27/16
PIPR
10/27/16
NO CHANGE
Target $33
PIPR
Overweight
Piper survey suggests growth for Horizon's Krystexxa
Piper Jaffray analyst David Amsellem says his survey of 25 rheumatologists who treat patients with chronic refractory gout and who are at least familiar with Horizon Pharma's Krystexxa suggest usage of the product is likely to broaden. The analyst points out that 76% of the respondents believe Krystexxa is a very effective option for the treatment of chronic refractory gout. He continues to believe Horizon is well positioned to deliver long-term annual earnings growth at least in the mid-teens. Amsellem sees an attractive valuation for Horizon shares and reiterates an Overweight rating on the name with a $33 price target.
11/28/16
SBSH
11/28/16
UPGRADE
Target $25
SBSH
Buy
Horizon Pharma upgraded to Buy from Neutral at Citi
Citi analyst Liav Abraham upgraded Horizon Pharma to Buy after resuming coverage of the name. The analyst views the risk/reward as favorable into the upcoming pivotal data for Actimmune in Friederich's Ataxia. The data are expected in late December. Abraham raised her price target for the shares to $25 from $21.
11/28/16
BMOC
11/28/16
NO CHANGE
BMOC
Horizon Pharma risk/reward positive into Phase 3 data, says BMO Capital
BMO Capital analyst Gary Nachman says that the risk/reward ratio for Horizon is positive going into the Phase 3 data for its Actimmune drug in Friedreich's Ataxia. The analyst thinks that there is only a 50% chance that the data will be successful;. However, he says that the risk/reward ratio is "favorable," based on how he thinks the shares will perform in the wake of the event. He keeps a $29 price target and an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.